Litcius/Paper detail

Completion axillary lymph node dissection for the identification of pN2–3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial

Jana de Boniface, Matilda Appelgren, Robert Szulkin, Sara Alkner, Yvette Andersson, Leif Bergkvist, Jan Frisell, Oreste ­Gentilini, Michalis Kontos, Thorsten Kühn, Dan Lundstedt, Birgitte Vrou Offersen, Roger Olofsson Bagge, Toralf Reimer, Malin Sund, Peer Christiansen, Lisa Rydén, Tove Filtenborg Tvedskov

2024The Lancet Oncology33 citationsDOI

Topics & Concepts

Post-hoc analysisMedicineDissection (medical)Lymph nodePost hocAdjuvantIdentification (biology)Randomized controlled trialNode (physics)SurgeryOncologyInternal medicineBiologyBotanyStructural engineeringEngineeringAdvanced Breast Cancer TherapiesBreast Cancer Treatment StudiesHER2/EGFR in Cancer Research
Completion axillary lymph node dissection for the identification of pN2–3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial | Litcius